Effect of Shikoni on Phosphomonoesterase Activity of Mycobaterium Tuberculosis Protein Tyrosine Phosphotases (PTPs)

Abdulhakeem Funsho Ahmed¹

Section:Research Paper, Product Type: Journal-Paper
Vol.9 , Issue.1 , pp.1-4, Jun-2022

Online published on Jun 30, 2022

Copyright © Abdulhakeem Funsho Ahmed . This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 

View this paper at   Google Scholar | DPI Digital Library

XML View     PDF Download

How to Cite this Paper

Abstract :
Several factors such as patient noncompliance and drug resistance affect the success rate of conventional treatments against tuberculosis and other pathogenic diseases; therefore there is need to improve the available therapeutic ways used in targeting tuberculosis treatment as well as design of new drugs that could act more rapidly on them. This research aimed to determine the effect of shikoni on phosphomonoesterase activity of mycobacterium tuberculosis using protein tyrosine phosphatases as enzyme inhibitor. Purified homogenous PTPs were obtained and shikoni phosphomonoesterase activity was determined by measuring the p-nitrophenol releases from the pNPP substrate. PTP acts as potential drug target which enables strategies to develop modern treatment regimen and regulate the levels of protein tyrosine phosphorylation under normal and pathological conditions.

Key-Words / Index Term :
Shikoni, Phosphatases activity, Mycobacterium Tuberculosis, Protein Tyrosine Phosphatases (PTPs)

References :
[1] Floyd, K., Raviglione, M., Glaziou, P. “Global burden and epidemiology of tuberculosis”. Clin. Chest Med., 30:621636. 2009.
[2] Castandet J., Prost J., Peyron P., Anes E., Cozozone A. et.al. “Tyrosine Phosphate MptpA of Mycobacterium tuberculosis Inhibits Phagocytosis and increase actin Polymerization in Macrophages.” Elsevier Journal of Research in Mycrobiology. 156, pp. 1005 – 1013. 2005.
[3] World Health Organization (WHO), Global tuberculosis report, 2013.
[4] Greenstein AE, Grundner C, Echols N, Gay LM, Lombana TN et al. “Structure/function studies of Ser/Thr and Tyr protein phosphorylation in Mycobacterium tuberculosis”. J Mol Microbiol Biotechnol 9: 167-181. doi:10.1159/000089645. PubMed: 16415590. 2005.
[5] Ruddraraju K., Aggarwal D., Zhang Z. “Therapeutic targeting of protein tyrosine phosphatases from Mycobacterium tuberculosis”. MDPI Journal of Microorganism. Vol. 9 (14). pp. 1 – 13. 2021.
[6] Munro, S.A.; Lewin, S.A.; Smith, H.J.; Engel, M.E.; Fretheim, A.; Volmink, J. Patient adherence to tuberculosis treatment: A systematic review of qualitative research. PLoS Med. 4, pp. 238. 2007
[7] 2019 Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline; World Health Organization: Geneva, Switzerland, 2019.
[8] Zhang, Y. The magic bullets and tuberculosis drug targets. Annu. Rev. Pharmacol. Toxicol. 45, 529–564. 2005.
[9] Bohmer F., Szedlacsek S., Tabernero L., Ostman A., Hertog J. “Protein tyrosine phosphatase structure-function relationship in regulation and pathogenosis”. The FEBS Journal. 280, pp. 413 – 431. 2013.
[10] S.A.Morris, “Genetic Diversity of Mycobacteriophages and the Unique Abilities of Cluster K”. The Corinthian, Vol. 18, Issue. 1, Article 5, 2017 .
[11] S. Hawtrey,L. Lovell, R. King, “Isolation, Characterization, and Annotation: The Search for Novel Bacteriophage Genomes”, The Journal of Experimental Secondary Science, Vol. 1, Issue. 2, pp. 1-9, 2011.
[12] Satish R., Desouza A. “Isolation of Mycobacteriophage: Novel tool to treat mycobacterium spp”. ISROSET, International Journal of Scientific Research in Biological Sciences. Vol. 5(2) pp. 46 – 50. 2018.